T-DXd
Lung Cancer
Final analysis results and patient-reported outcomes from DESTINY-Lung02-A dose-blinded, randomized, Phase 2 Study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC
Jänne PA, Goto Y, Kubo T, et al.
Thorac Oncol. 2025:S1556-0864(25)00981-5. doi: 10.1016/j.jtho.2025.07.129.
I-DXd
Lung Cancer
Multidimensional analysis of B7 homolog 3 (B7-H3) RNA expression in small-cell lung cancer molecular subtypes
Gay CM, Owonikoko TK, Byers LA, et al.
Clin Cancer Res. 2025;31(16):3476-3482. doi: 10.1158/1078-0432.CCR-24-3981.
Pexidartinib
Hematology
Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor
Dai D, Tecson K, Pan I, Ye X, Tap
Future Oncol. 2025;21(19):2515-2524. doi: 10.1080/14796694.2025.2527586.
HER3-DXd
Lung Cancer
Patritumab deruxtecan (HER3-DXd; MK-1022) in non–small cell lung cancer after platinum-based chemotherapy and immunotherapy
Steuer CE, Hayashi H, Su W-C, et al.
J Clin Oncol. 2025;43(25):2816-2826. doi: 10.1200/JCO-24-02744.
Other/Multi
Breast Cancer
Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: A discrete choice experiment study
Arpino G, De Angelis C, Gerratana L, et al.
BMC Cancer. 2025 May 22;25(1):920. doi: 10.1186/s12885-025-14308-4.
Valemetostat
Hematology
Effect of mild to moderate hepatic impairment on valemetostat pPharmacokinetics: An Open-Label, Phase I Study
Tachibana M, Craveiro TV, Marbury TC, et al.
Clin Pharmacol Drug Dev. 2025;14(8):631-641. doi: 10.1002/cpdd.1544.
T-DXd
Gastric Cancer
Trastuzumab deruxtecan or ramucirumab plus pacitaxel in gastric cancer
Shitara K, Van Cutsem E, Gümüş M, et al.
N Engl J Med. 2025;393(4):336-348. doi: 10.1056/NEJMoa2503119.
Dato-DXd
Lung Cancer
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
Cascone T, Bonanno L, Guisier F, et al.
Nat Med. 2025;31(8):2788-2796. doi: 10.1038/s41591-025-03746-z.
Pexidartinib
Other/Multi
TURALIO® risk evaluation and mitigation strategy (tREMS) program: 5-year retrospective hepatic safety assessment
Waheed Rajper A, Dharmani C, Chilakapati L, Fofah O, Wooddell MJ
Future Oncol. 2025 May 29:1-7. doi: 10.1080/14796694.2025.2509409. Epub ahead of print.
HER3-DXd
Breast Cancer Colorectal Cancer Lung Cancer
Integrated two-analyte population pharmacokinetics model of patritumab deruxtecan (HER3-DXd) monotherapy in patients with solid tumors
Xu Y, Lee M, Joshi R, et al.
Clin Pharmacokinet. 2025 May 23. doi: 10.1007/s40262-025-01521-4. Epub ahead of print.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28